Aurobindo Pharma Ltd, fiscal second-quarter profit rose 33.2%, beating analysts' estimates, on higher sales of generic drugs in the US. The Sales grew by sharp 51% YoY to Rs 2881.22 crore for the quarter ended September 2016. The Operating Profit margins slightly up by 146 bps YoY to 24.61%. Consequently, Operating profit grew by 19% YoY to Rs 929.21 crore. After 32% decrease in other income to Rs 8.28 crore, PBIDTA grew by 18% YoY to Rs 937.49 crore. With lower interest cost (down by 104% YoY to Rs 2.65 crore) and even after higher depreciation (up by 19% YoY to Rs 110.20 crore), PBT grew by 32% YoY to Rs 829.94 crore. However, after the sharp rise in effective tax rate (up...